Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.37 |
| ▸ | REN | P00797 | 4/20 | 0.37 |
| ▸ | CTSD | P07339 | 2/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL981672 | 0.89 | ATM (0.40) | PTGDR2RENCTSDBACE1ATM | |
| SCHEMBL984991 | 0.88 | PTGDR2 (0.38) | PTGDR2RENCTSDBACE1ATM | |
| SCHEMBL981882 | 0.85 | PTGDR2 (0.40) | PTGDR2MAPTATMMEN1KMT2A | |
| SCHEMBL983940 | 0.84 | PTGDR2 (0.43) | PTGDR2MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL982927 | 0.84 | PTGDR2 (0.40) | PTGDR2RENCTSDBACE1ATM | |
| SCHEMBL980826 | 0.83 | CYP3A4 (0.38) | PTGDR2RENCTSDBACE1MAPT | |
| SCHEMBL981023 | 0.82 | ATM (0.40) | PTGDR2RENCTSDBACE1MAPT | |
| SCHEMBL983369 | 0.78 | MEN1 (0.39) | BACE1MAPTATMMEN1KMT2A | |
| SCHEMBL980979 | 0.77 | CTNNB1 (0.45) | PTGDR2TP53MAPT | |
| SCHEMBL981169 | 0.76 | ATM (0.39) | PTGDR2RENCTSDBACE1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2257545-B1 | PYRROLIDINYL DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2011-08-31 | — | — | EP | disclosed |
| US-20110021556-A1 | PYRROLIDINYL DERIVATIVES AND USES THEREOF | HOFFMAN-LA ROCHE, INC. (US) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021556-A1 | PYRROLIDINYL DERIVATIVES AND USES THEREOF | SLC6A3, MAOB, TPH2 | PTGDR2 373/4885REN 321/4885CTSD 1133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.